• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Tuesday, April 13, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Common bacteria modified to make designer sugar-based drug

Bioengineer by Bioengineer
March 2, 2021
in Chemistry
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Process paves a road to safe, ethical, and fast drug manufacturing

IMAGE

Credit: Rensselaer Polytechnic Institute

TROY, N.Y. — Envisioning an animal-free drug supply, scientists have — for the first time — reprogrammed a common bacterium to make a designer polysaccharide molecule used in pharmaceuticals and nutraceuticals. Published today in Nature Communications, the researchers modified E. coli to produce chondroitin sulfate, a drug best known as a dietary supplement to treat arthritis that is currently sourced from cow trachea.

Genetically engineered E. coli is used to make a long list of medicinal proteins, but it took years to coax the bacteria into producing even the simplest in this class of linked sugar molecules — called sulfated glycosaminoglycans –that are often used as drugs and nutraceuticals..

“It’s a challenge to engineer E. coli to produce these molecules, and we had to make many changes and balance those changes so that the bacteria will grow well,” said Mattheos Koffas, lead researcher and a professor of chemical and biological engineering at Rensselaer Polytechnic Institute. “But this work shows that it is possible to produce these polysaccharides using E. coli in animal-free fashion, and the procedure can be extended to produce other sulfated glycosaminoglycans.”

At Rensselaer, Koffas worked with Jonathan Dordick a fellow professor of chemical and biological engineering, and Robert Linhardt a professor of chemistry and chemical biology. All three are members of the Center for Biotechnology and Interdisciplinary Studies. Dordick is a pioneer in using enzymes for material synthesis and designing biomolecular tools for the development of better drugs. Linhardt is a glycans expert and one of the world’s foremost authorities on the blood-thinner heparin, a sulfated glycosaminoglycans currently derived from pig intestine.

Linhardt, who developed the first synthetic version of heparin, said engineering E. coli to produce the drug has many advantages over the current extractive process or even a chemoenzymatic process.

“If we prepare chondroitin sulfate chemoenzymatically, and we make one gram, and it takes a month to make, and someone calls us and says, ‘Well, now I need 10 grams,’ we’re going to have to spend another month to make 10 grams,” Linhardt said. “Whereas, with the fermentation, you throw the engineered organism in a flask, and you have the material, whether it’s one gram, or 10 grams, or a kilogram. This is the future.”

“The ability to endow a simple bacterium with a biosynthetic pathway only found in animals is critical for synthesis at commercially relevant scales. Just as important is that the complex medicinal product that we produced in E. coli is structurally the same as that used as the dietary supplement.” said Dordick.

Koffas outlined three major steps the team had to build into the bacteria so that it would produce chondroitin sulfate: introducing a gene cluster to produce an unsulfated polysaccharide precursor molecule, engineering the bacteria to make an ample supply of an energetically expensive sulfur donor molecule, and introducing a sulfur transferase enzyme to put the sulfur donor molecule onto the unsulfated polysaccharide precursor molecule.

Introducing a working sulfotransferase enzyme posed a particularly difficult challenge.

“The sulfotransferases are made by much more complex cells,” Koffas said. “When you take them out of a complex eukaryotic cell and put them into E. coli, they’re not functional at all. You basically get nothing. So we had to do quite a bit of protein engineering to make it work.”

The team first produced a structure of the enzyme, and then used an algorithm to help identify mutations they could make to the enzyme to produce a stable version that would work in E. coli.

Although the modified E. coli produce a relatively small yield — on the order of micrograms per liter — they thrive under ordinary lab conditions, offering a robust proof of concept.

“This work is a milestone in engineering and manufacturing of biologics and it opens new avenues in several fields such as therapeutics and regenerative medicine that need a substantial supply of specific molecules whose production is lost with aging and diseases,” said Deepak Vashishth, director of the CBIS. “Such advances take birth and thrive in interdisciplinary environments made possible through the unique integration of knowledge and resources available at the Rensselaer CBIS.”

###

“Complete biosynthesis of a sulfated chondroitin in Escherichia coli” was published today in Nature Communications with support from National Science Foundation Grant CBET-1604547. Dordick, Linhardt, and Koffas were joined in the research at Rensselaer by Abinaya Badri, Asher Williams, Adeola Awofiranye, Payel Datta, Ke Xia, Wenqin He, and Keith Fraser. Once published, the paper can be found using DOI:10.1038/s41467-021-21692-5.

About Rensselaer Polytechnic Institute

Founded in 1824, Rensselaer Polytechnic Institute is America’s first technological research university. Rensselaer encompasses five schools, 32 research centers, more than 145 academic programs, and a dynamic community made up of more than 7,900 students and over 100,000 living alumni. Rensselaer faculty and alumni include more than 145 National Academy members, six members of the National Inventors Hall of Fame, six National Medal of Technology winners, five National Medal of Science winners, and a Nobel Prize winner in Physics. With nearly 200 years of experience advancing scientific and technological knowledge, Rensselaer remains focused on addressing global challenges with a spirit of ingenuity and collaboration. To learn more, please visit http://www.rpi.edu.

Media Contact
Mary Martialay
[email protected]

Related Journal Article

http://dx.doi.org/10.1038/s41467-021-21692-5

Tags: BacteriologyBiomedical/Environmental/Chemical EngineeringBiotechnologyGeneticsMedicine/HealthPharmaceutical Science
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

Jan Rajchmann Award for OLED professor Karl Leo

April 12, 2021
IMAGE

Technique allows mapping of epigenetic information in single cells at scale

April 12, 2021

Poop core records 4,300 years of bat diet and environment

April 12, 2021

Centrifugal multispun nanofibers put a new spin on COVID-19 masks

April 12, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    852 shares
    Share 341 Tweet 213
  • Jonathan Wall receives $1.79 million to develop new amyloidosis treatment

    60 shares
    Share 24 Tweet 15
  • UofL, Medtronic to develop epidural stimulation algorithms for spinal cord injury

    56 shares
    Share 22 Tweet 14
  • A sturdier spike protein explains the faster spread of coronavirus variants

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

cancerPublic HealthInfectious/Emerging DiseasesCell BiologyClimate ChangeEcology/EnvironmentMedicine/HealthBiologyMaterialsGeneticsChemistry/Physics/Materials SciencesTechnology/Engineering/Computer Science

Recent Posts

  • Ancient ammonoids’ shell designs may have aided buoyancy control
  • Basketball Mathematics scores big at inspiring kids to learn
  • Past Global Changes Horizons – a new paleoscience magazine for teenagers and young adults
  • ETRI develops a haptic film activated by LEDs
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In